Email
mejemel@wpi.edu
Education
PhD in Molecular, Cellular, and Organismal Biology, University of Massachusetts Boston
BS in Biology, University of Massachusetts Boston
DEUG in Chemistry, University of Kaddi Ayyad - Morocco
Dr. Monir Ejemel is an Adjunct Teaching Professor in the Division of Graduate and Professional Studies at WPI. He teaches courses in Molecular Biology of the Cell, Antibody Therapeutics, and Virology. In his primary affiliation, he is a Research Scientist II at MassBiologics in Boston MA where he works on discovery and development of therapeutic and diagnostic monoclonal antibody/nanobodies for infectious disease (e.g. COVID-19, Lyme disease, Rabies, ETEC, and Hepatitis C), progressive nervous system disease (e.g. ALS), or cancer targets (e.g. melanoma).
He has deep knowledge of infectious disease, immunology, monoclonal antibody engineering, vaccine research and molecular biology with expertise in therapeutic biologics development, disease modeling, AAV vector engineering, and bioanalytical supporting in clinical studies. He has extensive hands-on experience with monoclonal antibody/nanobody screening, engineering and production, AAV, promoter design, Lentivirus/AAV production, liquid chromatography, multi-color flow cytometry, in/ex vivo drug validation, recombinant protein expression, purification and stable cell line development.
Dr. Ejemel previously held teaching positions at Tufts University School of Engineering, Massachusetts College of Pharmacy and Health Sciences, and the University of Massachusetts Boston.
Email
mejemel@wpi.edu
Education
PhD in Molecular, Cellular, and Organismal Biology, University of Massachusetts Boston
BS in Biology, University of Massachusetts Boston
DEUG in Chemistry, University of Kaddi Ayyad - Morocco
Dr. Monir Ejemel is an Adjunct Teaching Professor in the Division of Graduate and Professional Studies at WPI. He teaches courses in Molecular Biology of the Cell, Antibody Therapeutics, and Virology. In his primary affiliation, he is a Research Scientist II at MassBiologics in Boston MA where he works on discovery and development of therapeutic and diagnostic monoclonal antibody/nanobodies for infectious disease (e.g. COVID-19, Lyme disease, Rabies, ETEC, and Hepatitis C), progressive nervous system disease (e.g. ALS), or cancer targets (e.g. melanoma).
He has deep knowledge of infectious disease, immunology, monoclonal antibody engineering, vaccine research and molecular biology with expertise in therapeutic biologics development, disease modeling, AAV vector engineering, and bioanalytical supporting in clinical studies. He has extensive hands-on experience with monoclonal antibody/nanobody screening, engineering and production, AAV, promoter design, Lentivirus/AAV production, liquid chromatography, multi-color flow cytometry, in/ex vivo drug validation, recombinant protein expression, purification and stable cell line development.
Dr. Ejemel previously held teaching positions at Tufts University School of Engineering, Massachusetts College of Pharmacy and Health Sciences, and the University of Massachusetts Boston.
Office
Off-Campus
Professional Highlights & Honors
Patent # WO2021226179A2 - "Anti-sars-cov-2 spike protein antibodies and methods of use". Inventors: Yang Wang, Mark S.J. KLEMPNER, Qi Li, Monir EJEMEL, 2021
Patent # WO2022192687A1 - "Synthetic promoters for gene therapy and protein expression". Inventors: Yang Wang, Mark S. Klempner, Monir Ejemel, Qi Li, Zuoshang Xu, 2022